Research progress of targeted therapy in human epidermal growth factor receptor-2 positive breast cancer

doi:10.3877/cma.j.issn.1674-0793.2021.06.013

Abstract

Abstract:

Traditional treatments for breast cancer include surgery, radiotherapy and chemotherapy. Targeted therapy has become an important treatment method for breast cancer because of its strong specificity and low toxicity. Human epidermal growth factor receptor-2 (HER-2) positive breast cancer has strong invasiveness and poor prognosis. The advent of trastuzumab improves the prognosis of HER-2-positive breast cancer. Since then, a series of anti-HER-2 targeted therapies have been used for clinical research and treatment, including pertuzumab, lapatinib, lenatinib, pyrotinib and ado-trastuzumab emtansine. This article reviews the current status of anti-HER-2 drugs with different mechanisms of action in the targeted therapy of HER-2-positive breast cancer.

Key words: Breast neoplasms, Targeted therapy, Receptor, epidermal growth factor, HER-2

Mengmeng Han, Xueyuan Feng, Ning Ma. Research progress of targeted therapy in human epidermal growth factor receptor-2 positive breast cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2021, 15(06): 453-458.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2021.06.013

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2021/V15/I06/453

References 39

[1]	Liao N. HER2-positive breast cancer, how far away from the cure?-on the current situation of anti-HER2 therapy in breast cancer treatment and survival of patients[J]. Chin Clin Oncol, 2016, 5(3): 41.
[2]	Gallagher CM, More K, Masaquel A, et al. Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice[J]. Springerplus, 2016, 5: 395.
[3]	Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J]. J Clin Oncol, 2014, 32(33): 3744-3752.
[4]	Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J]. N Engl J Med, 2011, 365(14): 1273.
[5]	Cameron D, Piccart-gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial[J]. The Lancet, 2017, 389(10075): 1195-1205.
[6]	Earl HM, Hiller L, Vallier AL, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial[J]. Lancet, 2019, 393(10191): 2599-2612.
[7]	Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial[J]. Lancet, 2019, 393(10191): 2591-2598.
[8]	Conte P, Frassoldati A, Bisagni G, et al. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase Ⅲ randomized Short-HER study[J]. Ann Oncol, 2018, 29: 2328-2333.
[9]	Joensuu H, Fraser J, Wildiers H, et al. Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial[J]. JAMA Oncol, 2018, 4(9): 1199-1206.
[10]	Tolaney SM, Guo H, Pernas S, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer[J]. J Clin Oncol, 2019, 37(22): 1868-1875.
[11]	Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study[J]. J Clin Oncol, 2010, 28(12): 2024-2031.
[12]	Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort[J]. Lancet, 2010, 375(9712): 377-384.
[13]	Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J]. N Engl J Med, 2012, 366(7): 1273-1283.
[14]	Slamon DJ, Leyland-jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001, 344(11): 783-792.
[15]	Marty M, Cognetti F, Maraninchi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group[J]. J Clin Oncol, 2005, 23(19): 4265-4274.
[16]	Wardley AM, Pivot X, Morales-vasquez F, et al. Randomized phase Ⅱ trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer[J]. J Clin Oncol, 2010, 28(6): 976-983.
[17]	Robert N, Leyland-jones B, Asmar L, et al. Randomized phase Ⅲ study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer[J]. J Clin Oncol, 2006, 24(18): 2786-2792.
[18]	Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol, 2016, 17(6): 791-800.
[19]	Shao Z, Pang D, Yang H, et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(3): e193692.
[20]	Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase Ⅲ KRISTINE study[J]. J Clin Oncol, 2019, 37(25): 2206-2216.
[21]	van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): A multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(12): 1630-1640.
[22]	von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer[J]. N Engl J Med, 2017, 377(2): 122-131.
[23]	Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(4): 519-530.
[24]	边莉，徐兵河，邸立军, 等. 重组抗HER2人源化单克隆抗体联合长春瑞滨治疗HER2阳性转移性乳腺癌随机对照Ⅲ期临床研究[J]. 中华医学杂志, 2020, 100(30): 2351-2357.
[25]	Cameron D, Casey M, Press M, et al. A phase Ⅲ randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses[J]. Breast Cancer Res Treat, 2008, 112(3): 533-543.
[26]	Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 1688-1700.
[27]	Chan A, Moy B, Mansi J, et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase Ⅲ ExteNET trial[J]. Clin Breast Cancer, 2021, 21(1): 80-91. e7.
[28]	Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase Ⅲ NALA trial[J]. J Clin Oncol, 2020, 38(27): 3138-3149.
[29]	Ma F, Ouyang Q, Li W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: A randomized, phase Ⅱ study[J]. J Clin Oncol, 2019, 37(29): 2610-2619.
[30]	Yan M, Bian L, Hu X, et al. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): A randomized, double-blind, placebo-controlled phase 3 study[J]. Transl Breast Cancer Res, 2020, 1: 13.
[31]	Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): A multicentre, open-label, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2021, 22(3): 351-360.
[32]	Lin NU, Murthy RK, Anders CK, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB)[J]. J Clin Oncol, 2020, 38(15_suppl): 1005-1005.
[33]	Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer[J]. N Engl J Med, 2019, 382(7): 597-609.
[34]	Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2012, 367(19): 1783-1791.
[35]	Meisel JL, Venur VA, Gnant M, et al. Evolution of targeted therapy in breast cancer: where precision medicine began[J]. Am Soc Clin Oncol Educ Book, 2018, 38: 78-86.
[36]	von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. N Engl J Med, 2019, 380(7): 617-628.
[37]	Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer[J]. N Engl J Med, 2019, 382(7): 610-621.
[38]	Modi S, Andre F, Krop IE, et al. Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis[J]. J Clin Oncol, 2020, 38(15_suppl): 1036-1036.
[39]	Modi S, Saura C, Yamashita T, et al. Abstract PD3-06: updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer[C]// Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas. 2021.

Please choose a citation manager

Content to export